logo
Plus   Neg
Share
Email

A.O. Smith Guides FY20 Adj. EPS In Line With Estimates - Quick Facts

While reporting financial results for the fourth quarter on Tuesday, A.O. Smith Corp. (AOS) initiated adjusted earnings and sales growth guidance for the full-year 2020, which excludes the potential impact to its businesses from the developing coronavirus originating in China.

For fiscal 2020, the company now projects adjusted earnings in a range of $2.40 to $2.50 per share on sales growth between 4.5 and 5.5 percent. The midpoint of the earnings guidance represents a ten percent increase over 2019 earnings per share.

On average, analysts polled by Thomson Reuters expect the company to report earnings of $2.48 per share on sales growth of 2.0 percent to $3.08 billion for the year. Analysts' estimates typically exclude special items.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Moderna said Tuesday that it has reached an agreement with the U.S. to initially supply 100 million doses of its experimental vaccine for COVID-19, mRNA-1273. The U.S. government has awarded up to $1.525 billion for the vaccine. Las Vegas, Nevada-based Mr. Wok Foods has recalled about 200,000 pounds of meat and poultry products for misbranding and undeclared allergens, the U.S. Department of Agriculture's Food Safety and Inspection Service or FSIS said. The recalled products may contain known allergens such as milk, wheat, soy, peanuts, or oysters. They may also contain MSG, sesame products, or sulfites. The U.S. Food and Drug Administration approved the first oral drug to treat patients two months of age and older with spinal muscular atrophy (SMA) that can be taken at home. Roche subsidiary Genentech's Evrysdi (risdiplam) is also the second FDA-approved drug to treat this rare and often fatal genetic disease affecting muscle strength and movement.
RELATED NEWS
Follow RTT